cytarabine has been researched along with gsk-2816126 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agrawal-Singh, S; Berdel, WE; Dugas, M; Ehninger, G; Göllner, S; Hansen, K; Herold, S; Jeremias, I; Klein, HU; Köhler, G; Lerdrup, M; Müller, LP; Müller-Tidow, C; Oellerich, T; Pabst, C; Pan, KT; Rohde, C; Sauer, T; Schenk, T; Serve, H; Spiekermann, K; Stölzel, F; Tavor, S; Thiede, C; Urlaub, H; Vick, B; Wickenhauser, C; Zelent, A | 1 |
1 other study(ies) available for cytarabine and gsk-2816126
| Article | Year |
|---|---|
Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Blotting, Western; Bortezomib; CDC2 Protein Kinase; Cell Line, Tumor; Cyclin-Dependent Kinases; Cytarabine; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Histones; Homeodomain Proteins; HSP90 Heat-Shock Proteins; Humans; Immunohistochemistry; Immunoprecipitation; Indoles; Leukemia, Myeloid, Acute; Male; Mass Spectrometry; Mice; Middle Aged; Neoplasm Transplantation; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proteomics; Pyridones; Young Adult | 2017 |